- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Alkacel ( Melphalan )
Alkacel (melphalan) is an alkylating agent indicated for the palliative treatment of multiple myeloma and for the treatment of advanced ovarian adenocarcinoma. It belongs to the nitrogen mustard class and works by cross-linking DNA strands, preventing cancer cell replication and triggering apoptosis. Melphalan is a cytotoxic chemotherapy drug that suppresses rapidly dividing cells, including malignant plasma cells in multiple myeloma. It is used under the supervision of an oncologist or hematologist and requires regular monitoring of blood counts. The 2 mg tablet is used to construct individualized oral dosing regimens.
Usual adult dose: For multiple myeloma, a common oral regimen is 0.15 mg/kg per day in divided doses for 7 days, combined with prednisone, and repeated every 6 weeks. An alternative regimen is 0.25 mg/kg per day for 4 days, repeated every 4 to 6 weeks. The dose is calculated by the prescriber and may be adjusted according to body weight and blood counts. Melphalan should be taken on an empty stomach (1 hour before or 2 hours after a meal) with a full glass of water. The tablets must be swallowed whole, not crushed or chewed. The 2 mg tablet allows fine dose adjustment. Treatment cycles are repeated only when the bone marrow has recovered, as indicated by adequate white blood cell and platelet counts. If a dose is missed, it should be reported to the treating healthcare team; the next dose should not be doubled.
Dosage form: Film-coated tablets: 2 mg (white to off-white, round, biconvex, imprinted with the strength). Available in bottles of 50 tablets.
Onset of action: Myelosuppression, the expected pharmacologic effect, reaches its lowest point (nadir) approximately 2 to 3 weeks after each treatment cycle. Clinical response in multiple myeloma, measured by reduction in monoclonal protein and improvement in blood counts, may take several weeks to months of repeated cycles. Melphalan is absorbed after oral administration, with peak plasma concentrations within 1 to 2 hours.
Duration of action: The elimination half-life of melphalan is approximately 1.5 hours, but the bone marrow suppressive effect is prolonged and cumulative. Therefore, treatment is given intermittently in cycles, with rest periods to allow hematologic recovery. The therapeutic effect may persist for months after completion of therapy.
Alcohol recommendation: Alcohol should be avoided during melphalan therapy. Alcohol may increase gastrointestinal irritation, including nausea and vomiting, and may worsen liver function. It can also contribute to dehydration, which is undesirable in patients receiving cytotoxic chemotherapy. Patients should discuss any alcohol use with their oncologist.
Most common side effects: Bone marrow suppression is the dose-limiting toxicity and includes leukopenia, thrombocytopenia, and anemia. Complete blood counts must be monitored before each cycle and more frequently during the nadir period. Other common adverse effects are nausea, vomiting, diarrhea, oral mucositis, and loss of appetite. Nausea and vomiting can often be controlled with antiemetic therapy. Secondary malignancies, particularly acute leukemia and myelodysplastic syndromes, have been reported after long-term use. Hypersensitivity reactions, including anaphylaxis, may occur. Pulmonary fibrosis and interstitial pneumonitis are rare but serious. Melphalan is contraindicated in pregnancy and breastfeeding; women of childbearing potential must use effective contraception during treatment. The drug should not be used in patients with severe bone marrow suppression or known hypersensitivity to melphalan. Alkacel is available only by prescription and must be prescribed and supervised by a healthcare professional experienced in oncology.
Would you like to try Alkacel (Melphalan) without a prescription?
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
